Biofrontera

Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all key financial metrics, driven by a 32.9% YoY revenue surge to $12.0M vs. the $9.5M expected. Gross margin reached 80.0%, benefiting from a strategic cost restructuring. The GAAP net loss of $0.6M was substantially narrower than the $1.25M loss anticipated, resulting in a GAAP EPS beat of -$0.05 vs. the -$0.105 consensus. The company is approaching Adjusted EBITDA breakeven, underpinned by strong Ameluz® demand and disciplined expense management.